You are here

Genentech

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Xtalks

clinical trials

Multiple Myeloma

adaptive trial design

Flag link:

Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC

Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC

BioSpace

non-squamous cell non-small cell lung cancer

Flag link:

Tecentriq could be first front-line SCLC therapy approved in two decades

Tecentriq could be first front-line SCLC therapy approved in two decades

BioCentury

extensive-stage small cell lung cancer

Flag link:

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Xconomy

Jecure Therapeutics

Flag link:

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

Yahoo/Guru Focus

acute myeloid leukemia

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug

Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug

Fierce Biotech

Flag link:

Roche’s Tecentriq gets fast review in triple negative breast cancer

Roche’s Tecentriq gets fast review in triple negative breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'

Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'

Endpoints

Flag link:

Roche and AbbVie Push Towards First-Line CLL Treatment

Roche and AbbVie Push Towards First-Line CLL Treatment

BioSpace

clinical trials

chronic lymphocytic leukemia

Flag link:

Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say

Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say

Fierce Biotech

Flag link:

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Endpoints

Flag link:

Sanofi, Genentech Both Eye U.S. Expansions; Could Add up to 2,300 Jobs

Sanofi, Genentech Both Eye U.S. Expansions; Could Add up to 2,300 Jobs

BioSpace

Flag link:

Roche and Novartis Strengthen Their Presence in the MS Market

Roche and Novartis Strengthen Their Presence in the MS Market

BioSpace

multiple sclerosis

Flag link:

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic

Endpoints

Flag link:

Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling

Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling

BioSpace

Flag link:

Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Yahoo/Zacks.com

systematic juvenile idiopathic arthritis

Flag link:

Roche CEO Severin Schwan is keeping his hand on the budget ax

Roche CEO Severin Schwan is keeping his hand on the budget ax

Endpoints

Flag link:

New Flu Season, New Flu Drug from Genentech

New Flu Season, New Flu Drug from Genentech

BioSpace

Flag link:

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

Endpoints

Flag link:

Pages